A White Paper on the Role & Mechanism of Action of Cannabinoids In Topical Treatments Against Common & Antibiotic Resistant Pathogens
Antibiotic resistance is a critical issue among the global healthcare community, with the World Health Organization identifying 12 increasingly antibiotic resistant pathogens and other organizations reporting increased rates of MRSA in hospitals and communities.
Current in-vitro scientific evidence suggests that cannabinoids including CBG, CBD, THC, CBN, and CBC possess potent activity against a wide range of pathogenic bacteria. These cannabinoids present an opportunity to develop novel and highly effective topical antibiotic applications based on three key discoveries:
- Several cannabinoids have demonstrated potent antibacterial activity at non-cytotoxic concentrations against various strains of gram-positive bacteria including the difficult-to-treat, methicillin-resistant Staphylococcus aureus (MRSA).
- CBG demonstrated superior antimicrobial potency as a biofilm inhibitor and persister cell eradicator.
- Several cannabinoids displayed potent antibacterial activity against E. coli and other gram-negative bacteria when co-administered with specific antibiotics known to disrupt the bacterial outer membrane.
LAVVAN’s advanced cellular agriculture platform offers a way to produce high-quality, pure cannabinoid ingredients to keep pace with the anticipated increase in research around novel cannabinoids’ antimicrobial use cases and ensuring the stable supply demanded by the health and pharmaceutical markets.
Download our whitepaper for an introduction to the potential of topical cannabinoid applications to combat the global growth of antibiotic resistant pathogens.